Spatially distributed potential of landfill biogas production and electric power generation in Brazil.

Due to the relatively low investment, operation costs, and technical requirements, landfills are still the most widespread alternative for final disposal of municipal solid waste (MSW). The biogas produced in the landfill, a renewable energy source, may be an important alternative for electric power generation. Brazil has a significant number of operating landfills, which receive the most part of the collected MSW. However, the country has only 17 landfill biogas power plants (LBPPs), resulting in about 122 MW of capacity. The United Kingdom, for instance, which is about 3 times smaller than Brazil in population, has 442 LBPPs (corresponding to 1051 MW of capacity). This fact highlights a considerable unexplored potential of landfill biogas in Brazil. It is also important to estimate this potential throughout the country to provide information for the government, researchers and companies in decision making, planning and formulation of public policies regarding this use of landfill biogas. Therefore, this study aims at estimating the spatially distributed potential of landfill biogas production that can be used for electric power generation in Brazil from 2015 to 2045, considering two scenarios: (i) operating sanitary landfills and (ii) hypothetical scenario of Territorial Arrangements (TA) comprising every Brazilian city, considering one landfill per TA. The total installed capacity estimated in 2018 for scenario 1 is about 523 MW and 87% of this number are related to LBPPs bigger than 1 MW. In this same year, the total installed capacity estimated for scenario 2 is 768 MW and 95% of this number are related to LBPPs bigger than 1 MW. These results emphasize that Brazil has a considerable unexplored potential of landfill biogas and the importance of municipal consortiums for MSW management.

Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies.

We have previously shown that leukemia-specific cytotoxic T cells (CTL) can be generated from the bone marrow of most patients with B-cell precursor acute leukemias. If these antileukemia CTL are to be used for adoptive immunotherapy, they must have the capability to circulate, migrate through endothelium, home to the bone marrow, and, most importantly, lyse the leukemic cells in a leukemia-permissive bone marrow microenvironment. We demonstrate here that such antileukemia T-cell lines are overwhelmingly CD8(+) and exhibit an activated phenotype. Using a transendothelial chemotaxis assay with human endothelial cells, we observed that these T cells can be recruited and transmigrate through vascular and bone marrow endothelium and that these transmigrated cells preserve their capacity to lyse leukemic cells. Additionally, these antileukemia T-cell lines are capable of adhering to autologous stromal cell layers. Finally, autologous antileukemia CTL specifically lyse leukemic cells even in the presence of autologous marrow stroma. Importantly, these antileukemia T-cell lines do not lyse autologous stromal cells. Thus, the capacity to generate anti-leukemia-specific T-cell lines coupled with the present findings that such cells can migrate, adhere, and function in the presence of the marrow microenvironment enable the development of clinical studies of adoptive transfer of antileukemia CTL for the treatment of ALL.

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.

In contrast to other neoplasms, antigen-specific autologous cytolytic T cells have not been detected in patients with human pre-B-cell leukemias. The absence of efficient B7 family (B7-1/CD80; B7-2/CD86) -mediated costimulation has been shown to be a major defect in tumor cells' capacity to function as antigen-presenting cells. We show here the generation of autologous anti-pre-B-cell leukemia-specific cytolytic T-cell lines from the marrows of 10 of 15 patients with pre-B-cell malignancies. T-cell costimulation via CD28 is an absolute requirement for the generation of these autologous cytolytic T cells (CTL). Although costimulation could be delivered by either bystander B7 transfectants or professional antigen-presenting cells (indirect costimulation), optimal priming and CTL expansion required that the costimulatory signal was expressed by the tumor cell (direct costimulation). These anti-pre-B-cell leukemia-specific CTL lysed both unstimulated and CD40-stimulated tumor cells from each patient studied but did not lyse either K562 or CD40-stimulated allogeneic B cells. Cytolysis was mediated by the induction of tumor cell apoptosis by CD8+ T cells via the perforin-granzyme pathway. Although we were able to generate anti-leukemia-specific CTL from the bone marrow, we were unable to generate such CTL from the peripheral blood of these patients. These studies show that antigen-specific CTL can be generated from the bone marrow of patients with pre-B-cell leukemias and these findings should facilitate the design of adoptive T-cell-mediated immunotherapy trials for the treatment of patients with B-cell precursor malignancies.